SCIENTIFIC PROGRAMME

Thursday, September 22, 2022

 

09.00                   Registration Opens

10.00 – 10.10    Welcome Address

                              Michael von Bergwelt, Munich, Germany

10.10 – 11.40    Plenary Symposium 1: Emerging Concepts / New Agents (including Immunometabolism)

Chair: Stefan Endres, Munich, Germany & Gabriela Wiedemann, Munich, Germany

 

10.10 – 10.40    01.01 Dissecting and modulating reactive anti-tumor immunity in human cancer 

Daniela Thommen, Amsterdam, The Netherlands

10.40 – 11.10    01.02 CH13L1: a novel NK cell related immune check point

          Maria Rescigno, Pieve Emanuele (Milano), Italy

 

11.10 – 11.40    01.03 Reprogramming of macrophages by modulators of premetastatic niche formation and their impact on
                            immune checkpoint blockade

Marisol Soengas, Madrid, Spain

11.45 – 12.15   Coffee Break

12.15 - 13.45    Plenary Symposium 2: Tumor microenvironment

Chair: Marcus Bosenberg, New Haven, CT, USA & Michael Bergmann, Vienna, Austria

 

12.15 – 12.45    02.01 Investigating the impact of lymphatic transport in immunotherapy

                            Amanda Lund, New York, NY, USA

 

12.45 – 13.15    02.02 Immune cell communications in the tumor microenvironment

 Thorsten Mempel, Boston, MA, USA
 

13.15 – 13.45    02.03 Harnessing tumor-derived extracellular vesicles to modulate the TME 

Simon Heidegger, Munich, Germany

13.45 – 15.30    Lunch & Poster Viewing

15.30 – 17.30    Plenary Symposium 3: B cells in immunooncology

Chair: Mascha Binder, Halle, Germany & Eric Tartour, Paris, France

 

15.30 – 16.00    03.01 From B cells to tertiary lymphoid structures in NSCLC patients

 Marie-Caroline Dieu-Nosjean, Paris, France

16.00 – 16.30    03.02 Neoantigen-driven B cells promote CD8 T cell responses

          Nikhil Joshi, New Haven, CT, USA

16.30 – 17.00    03.03 Engineering B cells for cancer treatment

          Adi Barzel, Tel Aviv, Israel

 

17.00 – 17.15    03.04 Towards a B cell Vaccine for Tumour expressed Self-Antigens
                            Fernanda Escobar-Riquelme, Birmingham, United Kingdom

17.15 – 17.30    03.05 Understanding how epitope binding influences antibody dependent complement engagement for

                            therapy of B-cell malignancies
                            Sina Bondza, Uppsala, Sweden

17.30 - 19.00     Welcome Reception and Poster Viewing (at the venue)

Friday, September 23, 2022

 

08.30 – 09.30    Plenary Symposium 4: Vaccine Therapy

Chair: Niroshana Anandasabapathy, New York, United States & Tanja de Gruijl, Amsterdam, The Netherlands

08.30 - 09.00     04.01 IDH directed vaccines in Glioblastoma

 Michael Platten, Heidelberg, Germany

09.00 - 09.30     04.02 The generation of immunostimulatory exosomes programmed by oncolytic viruses

 Brian Lichty, Toronto, ON, Canada

09.30 – 10.30    Plenary Symposium 5: Pro & Contra Sessions for Critical Topics

Chair: Florian Bassermann, Munich, Germany & Ulrich Jäger, Vienna, Austria

 

09.30 – 10.00    05.01 Pro IO combination with chemotherapy 

          Mascha Binder, Halle, Germany

 

10.00 – 10.30    05.02 Contra: IO mono- or combo-therapy shall prevail 

          Stéphane Champiat, Villejuif, France

10.30 – 11.15    Coffee Break

11.15 – 12.45    Plenary Symposium 6: Precision Medicine Meets Immunotherapy (Immuno-Monitoring)

Chair: Pedro Romero, Lausanne, Switzerland & Chong Xian Pan, Boston, MA, USA

11.45 – 12.15    06.01 Single cell and spatial transcriptomics unravel a NASH-associated innate immunity contexture in 

 hepatocellular carcinoma associated with poor response to immunotherapy

 Maya Saleh, Bordeaux, France

 

12.15 – 12.45    06.02 Using PET to Image  Immune Cell Changes in Response to Therapy

 Elisabeth de Vries, Groningen, The Netherlands

 

12.45 – 13.00    06.03 Integrative analysis of neuroblastoma by single‐cell RNA sequencing identifies the NECTIN2‐TIGIT axis

                            as a target for immunotherapy

                            Judith Wienke, Utrecht, The Netherlands

 

13.00 – 13.15    06.05 An activation to memory differentiation trajectory of tumor-infiltrating lymphocytes informs 
                            metastatic melanoma outcomes
                            Niroshana Anandasabapathy, New York, NY, USA

 

13.15 – 14.30    Lunch & Poster Viewing

14.30 – 15.00    Satellite Symposium

Please click HERE for details

15.00 – 15.45    Plenary Symposium 7: Lifetime Achievement Award presented to Prof. Dr. Laurence Zitvogel

Chair: Michael von Bergwelt, Munich, Germany & Christoph Zielinski, Vienna, Austria

07.01 Microbiota-centered Interventions to circumvent primary resistance to I-O

Laurence Zitvogel, Villejuif, France

15.45 – 16.15     Coffee Break

16.15 – 17.30     Plenary Symposium 8: “Lost in Translation”

Chair: Bastian Schilling, Würzburg, Germany & Maya Saleh, Bordeaux, France

 

16.15 – 16.45     08.01 Will vaccination strategies come back of age in melanoma? 

  Tanja de Gruijl, Amsterdam, The Netherlands

 

16.45 – 17.15     08.02 What T cells see in context of immunotherapy

  Sine Reker Hadrup,  Lyngby, Denmark

 

17.15 – 17.30    08.03 MHJC-based large-scale screening of anti-tumor T cells in chronic lymphocytic leukemia reveals CD8+ T 
                            cells with specificity against the clonotypic B-cell receptor immunoglobulin
                            Yogesh Basavaraju, Copenhagen, Denmark

17.30 – 18.30     Plenary Session 9: Young Researcher Session (from submitted abstracts)

Chair: Sebastian Kobold, Munich, Germany & Volkmar Nüssler, Munich, Germany

 

17.30 – 17.45    09.01 Armoring anti-HER2 CAR-T cells with C-C-motive receptor 8 (CCR8) and a dominant negative TGF-b

                            receptor (DNR) to enable efficacy in solid tumor models
                            Thaddäus Strzalkowski, Munich, Germany

17.45 – 18.00    09.02 Bispecific antibodies enable synthetic agonistic receptor T cell therapy in melanoma
                            Florian Märkl, Munich, Germany

18.00 – 18.15    09.03 CD122-directed IL-2/anti-IL-2 complexes enhance abscopal responses to radiation combined with anti-

                             PD-1
                            Kateryna Onyshchenko, Freiburg, Germany

 

18.15 – 18.30    09.04 Secondary resistance to immunotherapy is associated with death and de-differentiation of activated T

                            Cells
                            Chen Qing, London, United Kingdom

 

18.30                    Poster Viewing with Presenters

20.00                    ITOC9 Conference Dinner


Saturday, September 24, 2022

 

08.00 – 09.00    Plenary Symposium 10: Cell Therapy in Solid Tumors

Chair: Philipp Beckhove, Regensburg, Germany & Justus Weber, Würzburg, Germany

 

08.00 – 08.30    10.01 Reengineering CAR T cells for optimized efficacy in solid tumors

          Sebastian Kobold, Munich, Germany

08.30 – 09.00    10.02 Enabling CAR T cells in solid tumors by check point blockade

 Prasad Adusumilli, New York, NY, USA

09.00 – 10.30    Plenary Symposium 11: Cell Therapy in Haematologic Diseases

Chair: Adrian Gottschlich, Munich, Germany & Tobias Feuchtinger, Munich, Germany

 

09.00 – 09.30    11.01 Single-cell approaches for identifying antigen dependent and independent toxicity in BiTEs and CAR T

                             cells

          Caleb Lareau, Standford, CA, USA

09.30 – 10.00    11.02 Novel approaches to cell therapy of myeloma

          Andrea Schmidts, Munich, Germany

10.00 – 10.30    11.03 T-cell receptors targeted to leukemia

 Johanna Olweus, Oslo, Norway

10.30 – 11.00    Coffee Break

11.00 – 12.45    Plenary Symposium 12: Combination Therapy (with a special focus on local IO)

Chair: José Saro, Abingdon, United Kingdom & Fabian Müller, Erlangen, Germany

11.00 – 11.30    06.04 Synergistic antitumor activity of pan-PI3K inhibition and immune checkpoint blockade in bladder 
                            cancer
                            Chong-Xian Pan, Boston, MA, USA


11.30 – 12.00    12.02 Local immune modulation and tumor ablation

          Gosse Adema, Nijmegen, The Netherlands
 

12.00 – 12.15    12.03 ISB 1442, a first-in-class CD38 and CD47 bispecific antibody innate cell modulator for the treatment of
                            CD38 positive hematological malignancies

                             Stefano Sammicheli, Lausanne, Switzerland

12.15 – 12.30    12.04 Re-directing CAR-T cells against solid tumors using T-SIGn-mediated antigen delivery and tumor
                            microenvironment reprogramming
                            Maria Sasso, Abingdon, United Kingdom

12.30 – 12.45    12.05 Tumor targeted innate immune checkpoint blockade for the treatment of Neuroblastoma using

                             Bifunctional antibodies
                            Fabian Schuurmans, Nijmegen, The Netherlands

 

12.45 – 13.00    Best Poster Awards & Closing Remarks

 

13.00 – 14.00    Lunch